According to the most recently available figures, more than 2,000 new oncology clinical trials have begun since 2023, demonstrating the continued need for innovative and effective cancer therapies. While many well-known targets have already yielded first-in-class biotherapeutics, the future of precision medicine depends on identifying novel targets and demonstrating - in the clinic - that they can be successfully drugged. This session explores strategies and successes of companies pioneering novel targets and modalities in solid tumors in the clinic. Participants will gain insights into how these candidates were selected and progressed, and the decision-making process involved in evaluating novel agents as monotherapies or as combinations.